NCT06538818

Brief Summary

In this study, 60 patients will be randomly assigned into two equal groups (30 patients for each group):

  • Age range between 40-55 years.
  • Female patients will participate in the study.
  • All patients will have hormonal therapy at least for 6 weeks.
  • All patients enrolled to the study will have their informed consent.
  • Patient referred from physician by carpal tunnel syndrome. (B) Exclusion Criteria: The potential participants will be excluded if they meet one of the following criteria:
  • Marked lymphedema.
  • Steroid injection for CTS.
  • Thrombosis propensity.
  • Cervical radiculopathy.
  • Brachial plexopathy

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Sep 2024

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 1, 2024

Completed
5 days until next milestone

First Posted

Study publicly available on registry

August 6, 2024

Completed
26 days until next milestone

Study Start

First participant enrolled

September 1, 2024

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2024

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2024

Completed
Last Updated

September 18, 2025

Status Verified

September 1, 2025

Enrollment Period

1 month

First QC Date

August 1, 2024

Last Update Submit

September 13, 2025

Conditions

Outcome Measures

Primary Outcomes (4)

  • Median nerve sensory and motor distal latency

    For assessing the Motor distal latency, the active recording electrode will be fastened on abductor pollicis brevis (APB) muscle and median nerve will be stimulated at wrist region with stimulator electrode, 8 cm proximal to the active electrode and then the distal latency will be recorded. Regarding the sensory distal latency, the recorder will be fastened on the third finger, and stimulator electrode will be placed 14 cm proximal to the recorder and will stimulate median nerve once at wrist and once at palm region, then distal latency will be recorded. Normal distal sensory latency of median nerve is of less than 3.6 and distal motor latency of median nerve less than 4.2. If only the sensory distal latency will long, patient has mild CTS, but if both sensory and motor distal latency will be long and denervation will not be observed in electromyography of APB, it is moderate CTS.

    3 weeks

  • pain using a visual analogue scale (VAS)

    Intensity of pain is another outcome measure will be used to evaluate treatment. Adults use the visual analogue scale (VAS), a one-dimensional assessment tool, particularly for chronic pain. The VAS is a continuous scale that consists of a line that is either vertical (VVAS) or horizontal (HVAS), usually 10 cm long, and is supported by two verbal descriptors, one for each symptom intensity. The patients will be thoroughly briefed on the instructions, reporting timeline, and vocal description anchors prior to the measurement.

    3 weeks

  • Baseline hydraulic hand dynamometer is used to measure hand grip strength

    . It is manufactured and serviced in the USA since 1978. It gives accurate grip strength readings without the subject being able to feel the handle move. The internationally accepted design ensures reliability, user convenience and measurement repeatability. Maximum reading remains until the unit is reset. The device comes with five position handles to improve comfort while using the dynamometer. The device Gauge is made of bourdon tube element with spring suspended movement that can viewed as pounds or kilograms.

    3 weeks

  • Boston Carpal Tunnel Questionnaire (BCTQ):

    Patients with CTS can assess their level of dysfunction and symptom severity using the BCTQ .It has two measurement scales: the BCTQ-F, which measures functional status, and the BCTQ-S, which measures symptom severity. The BCTQ-S employs eleven questions on a five-point rating system from 1 (no symptoms) to 5 (severe symptoms) to assess the frequency and intensity of pain, numbness, weakness, and loss of dexterity. The average scores of the 11 questions are used to analyze the results. The BCTQ-F has eight questions that are scored on a five-point scale from 1 (no trouble) to 5 (cannot do at all owing to hand or wrist symptoms) to assess the degree of difficulty in carrying out daily chores. The average scores of the eight questions are used to analyze the results.

    3 weeks

Study Arms (2)

Study group

EXPERIMENTAL

This group will include 30 patients who will receive Ultra Phonophoresis with a hyaluronic acid-containing gel 5 sessions per week for 3 weeks in addition to their physical therapy program and medical treatment.

Device: Ultra Phonophoresis

Control group:

NO INTERVENTION

This group will include 30 patients who will receive only their traditional physical therapy program and medical treatment.

Interventions

Therapeutic pulsed ultrasound using Phyaction UbMF ultrasound device in presence of a hyaluronic acid-containing gel will be applied gel pad over the wrist and along the course of median nerve at the carpal tunnel. The following parameters will be used: intensity of 1.0 W/em2 at a 1MHz frequency for 5 minutes and pulsed (25%) ultrasound waves to transfer the hyaluronic acid-containing gel. This therapy will be applied for 5 min/session, 5 d/wk, for 3 weeks. The following parameters will be used: * intensity of 1.0 W/cm2 * 1MHz frequency * pulsed (25%) * 5 min/session, 5 d/wk, for 3 weeks.

Study group

Eligibility Criteria

Age40 Years - 55 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility Details* All patients will have hormonal therapy at least for 6 weeks. * Patient referred from physician by carpal tunnel syndrome post mastectomy
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Age range between 40-55 years.
  • Female patients will participate in the study.
  • All patients will have hormonal therapy at least for 6 weeks.
  • All patients enrolled to the study will have their informed consent.
  • Patient referred from physician by carpal tunnel syndrome

You may not qualify if:

  • Marked lymphedema.
  • Steroid injection for CTS.
  • Thrombosis propensity.
  • Cervical radiculopathy.
  • Brachial plexopathy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cairo University

Cairo, Egypt

Location

MeSH Terms

Conditions

Carpal Tunnel Syndrome

Condition Hierarchy (Ancestors)

Median NeuropathyMononeuropathiesPeripheral Nervous System DiseasesNeuromuscular DiseasesNervous System DiseasesNerve Compression SyndromesCumulative Trauma DisordersSprains and StrainsWounds and Injuries

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Lecturer of physical therapy of surgery

Study Record Dates

First Submitted

August 1, 2024

First Posted

August 6, 2024

Study Start

September 1, 2024

Primary Completion

October 1, 2024

Study Completion

November 1, 2024

Last Updated

September 18, 2025

Record last verified: 2025-09

Data Sharing

IPD Sharing
Will not share

Locations